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Abstract 
Background 
Hepatitis C Virus (HCV), a single stranded RNA virus, affects millions of people worldwide 
and leads to chronic infection characterized by chronic inflammation in the liver and in 
peripheral immune cells. Chronic liver inflammation leads to progressive liver damage. 
MicroRNAs (miRNA) regulate inflammation (miR-155, -146a and -125b) as well as 
hepatocyte function (miR-122). 
Methods 
Here we hypothesized that microRNAs are dysregulated in chronic HCV infection. We 
examined miRNAs in the circulation and in peripheral monocytes of patients with chronic 
HCV infection to evaluate if specific miRNA expression correlated with HCV infection. 
Results 
We found that monocytes from chronic HCV infected treatment-naïve (cHCV) but not 
treatment responder patients showed increased expression of miR-155, a positive regulator of 
TNFα, and had increased TNFα production compared to monocytes of normal controls. After 
LPS stimulation, miR-155 levels were higher in monocytes from cHCV patients compared to 
controls. MiR-125b, which has negative regulatory effects on inflammation, was decreased in 
cHCV monocytes compared to controls. Stimulation of normal monocytes with TLR4 and 
TLR8 ligands or HCV core, NS3 and NS5 recombinant proteins induced a robust increase in 
both miR-155 expression and TNFα production identifying potential mechanisms for in vivo 
induction of miR-155. Furthermore, we found increased serum miR-155 levels in HCV 
patients compared to controls. Serum miR-125b and miR-146a levels were also increased in 
HCV patients. Serum levels of miR-122 were elevated in cHCV patients and correlated with 
increased ALT and AST levels and serum miR-155 levels. 
Conclusion 
In conclusion, our novel data demonstrate that miR-155, a positive regulator of inflammation, 
is upregulated both in monocytes and in the serum of patients with chronic HCV infection. 
Our study suggests that HCV core, NS3, and NS5 proteins or TLR4 and TLR8 ligands can 
mediate increased miR-155 and TNFα production in chronic HCV infection. The positive 
correlation between serum miR-155 and miR-122 increase in cHCV may be an indicator of 
inflammation-induced hepatocyte damage. 
Keywords 
Biomarker, MiR-122, MiR-155, MiR-125b, ALT, Inflammation 
Background 
Hepatitis C virus infection affects over 170 million people worldwide, and the majority of 
those have chronic hepatitis that can lead to progressive liver disease, cirrhosis and 
hepatocellular cancer. Elimination of the HCV virus by the immune system is a complex 
process and alterations in both innate and adaptive immune responses contribute to chronic 
HCV infection [1]. Chronic HCV infection is characterized by the presence and activation of 
inflammatory cells in the liver, and the persistent inflammation contributes to liver fibrosis 
and liver damage [2,3]. In addition to the local inflammation in the liver, a low-grade 
systemic inflammation was noted in several studies, specifically, increased pro-inflammatory 
cytokine levels and activation of blood monocytes was found in individuals with chronic 
HCV infection [4,5]. Our previous studies suggested that monocytes from cHCV patients 
produce increased levels of TNFα, and this was related to a loss of toll-like receptor tolerance 
that is a mechanism in healthy cells to prevent pro-inflammatory over-activation [6]. Other 
studies also showed a correlation between HCV virus levels, inflammation and liver injury in 
chronic HCV infection [7,8]. 
Innate immune responses provide the first line of defense to pathogens. Innate immune 
responses can be mediated by pathogen-derived signals such as lipopolysaccharide (LPS) 
from Gram-negative bacteria that bind to toll like receptor 4 (TLR4), or HCV core (viral core 
protein) and NS3 (non-structural viral protein) proteins from Hepatitis C virus (HCV) that 
can activate cells via TLR2 [9,10]. A recent study demonstrated that NS5 (non-structural 
viral protein) also induces TNFα in human Kupffer cells [11]. Moreover, viral envelope 
protein E2 has been shown to interact with CD81 and enhances the expression of activation-
induced cytidine deaminase and TNFα production in B cells [12]. The engagement of TLRs 
leads to the activation and expression of many genes that are directed to clear the pathogen. 
HCV, a single-stranded RNA virus, also interacts with TLR7/8, which recognizes small 
pieces of non-self nucleotides [13]. With the activation of many of the TLRs, the 
transcription factor NFκB is activated and subsequent inflammatory genes are transcribed. 
With the growing evidence for the roles of microRNAs (miRNAs) as posttranscriptional 
regulators of inflammation, we hypothesized that miRNAs involved in inflammation in 
monocytes may be dysregulated in HCV patients, thereby contributing to inflammatory cell 
activation. 
The miRNAs relevant to monocyte inflammatory activation are miR-155, miR-146a, and 
miR-125b as they regulate inflammation at multiple levels [14]. MicroRNA-155 is a positive 
regulator of TNFα, which is a key cytokine of inflammation and regulated at the 
transcriptional level by the transcription factor, NF-κB. Previous studies have found elevated 
TNFα levels in HCV patients, thus we aimed to investigate the role of miRNAs that are 
known to regulate TNFα. Other miRNAs that are involved in the regulation of TNFα directly 
or indirectly include miR-125b and miR-146a, which are the negative regulators of 
TLR4/LPS signaling [14,15]. 
In this study, we report increased expression of miR-155 in monocytes of patients with 
chronic HCV infection that is no longer present in individuals who underwent successful 
antiviral therapy. Our results demonstrate that miR-155 is also increased in the serum of 
cHCV patients along with miR-122, a microRNA abundant in hepatocytes. Our studies also 
identify possible mechanisms for in vivo miR-155 activation in chronic HCV infection. 
Methods 
Monocyte isolation and stimulation 
Monocytes were isolated from normal healthy controls and HCV infected patients using 
Ficoll-Paque density gradient centrifugation as described [16]. The patient information is 
given in detail in Table 1. Written consents were obtained from the blood donors enrolled in 
the study. The protocol for collecting blood is approved by the "Institutional Review Board" 
(IRB), called the "Committee for the Protection of Human Subjects in Research" at UMMS. 
LPS and CL075 were purchased from Sigma-Aldrich and Invivogen respectively. HCV NS3, 
NS5 and core recombinant proteins were purchased from BioDesign (USA). The experiment 
was set up in duplicates from the monocytes of healthy individuals. The LPS contamination 
of recombinant proteins was <0.01 EU/ml, detected by Limulus amebocyte assay as described 
earlier [10]. HCV E2 recombinant protein was obtained from MassBiologics (Boston, MA, 
USA) and contained undetectable endotoxin levels. 
Table 1 Clinical parameters of HCV Patients (peripheral blood monocytes isolation) 
Parameters HCV patients (Average± SEM) 
Gender: Responders: Male/female Naïve: Male/female 2/3 10/2 
Age: Responders: Naïve: 50.50± 8.17 42.62± 4.7 
AST (U/l) Naïve: 44.87± 5.2 
ALT (U/l) Naïve: 81.85± 15.63 
Viral load (Iu/ml): Naïve: 6X10
4
 - 9.4X10
5
 IU/ml 
RNA isolation and PCR analyses 
Total RNA was isolated with the miRNeasy kit (Qiagen). For mRNA analysis, RNA was 
transcribed into cDNA using Promega’s reverse transcription kit (Promega) and quantitative 
analyses of genes were performed using gene-specific primers on a Bio-Rad iCycler real time 
machine. Primer sequences were: TNFα, forward 5'-ATCTTCTCGAACCCCGAGTGA-3', 
reverse 5'-CGGTTCAGCCACTGGAGCT-3', TLR4, forward 5'- 
AGGCCGAAAGGTGATTGTTG -3', reverse 5'-CTGAGCAGGGTCTTCTCCAC-3' and 
TLR8, forward 5'-TGTGATGGTGGTGCTTCAAT-3', reverse 5'-
ATGCCCCAGAGGCTATTTCT-3'. The data was normalized to 18 S and fold change was 
calculated using delta-delta Ct method. 
miRNA analyses 
TaqMan miRNA Assays (Applied Biosystems) were employed for the detection of miRNAs 
as described [17]. In monocytes, RNU48 was used to normalize the Ct values between the 
samples. Serum samples were collected into serum separator tubes (BD Biosciences), 
centrifuged at 2000 rpm, aliquoted and stored at -80 °C. 100ul of serum from healthy controls 
and patient samples was used for total RNA isolation with miRNeasy kit (Qiagen). Synthetic 
C. elegans (cel)-miR-39 was spiked during the total RNA isolation process and used to 
normalize the real time PCR data. All PCR reactions were performed in duplicates, and 
miRNA data from serum samples was repeated twice. The patient information is given in 
Table 2. 
Table 2 Clinical parameters of HCV Patients used for serum miRNA isolation 
Parameters HCV patients (Average± SEM) 
Gender: Male/female 27/11 
Age 54.07 ± 1.92 
AST (U/l) 61.53 ± 7.31 
ALT (U/l) 99.03 ± 19.91 
Viral load (Iu/ml) 5X10
4
 – 9.3X106 
Genotype 1a, 1b, 2b, 3a 
Category HCV naïve: 19 HCV: 15 HCV non responders: 3 Hep B + C: 1 
Statistical analysis 
The non-parametric Mann–Whitney test or two-tailed t-test was employed for statistical 
analysis and p value less than 0.05 was considered significant. 
Results 
MiR-155 expression is increased in monocytes of treatment-naïve patients 
with chronic HCV infection 
Previous studies demonstrated that increased monocyte TNFα production in chronic HCV 
infection is causally linked to the presence of the HCV virus, circulating HCV core protein, 
and LPS [6,18]. Here we investigated patients with chronic HCV infection (cHCV) who were 
treatment-naïve and had detectable virus, sustained virological responder patients who have 
successfully cleared HCV infection after receiving standard therapy (HCV-responders), and 
healthy individuals as controls. We found that circulating monocytes of cHCV patients had 
significantly higher levels of miR-155 compared to sustained responders or normal controls 
(Figure 1A). In vitro LPS stimulation revealed that monocytes from cHCV patients had 
significantly higher LPS-induced miR-155 levels compared to normal control monocytes 
(Figure 1B). 
Figure 1 Induction of miR-155 in peripheral monocytes of chronic HCV treatment naïve 
patients. A. Total RNA was isolated from the monocytes of healthy volunteers (n = 6), 
chronic HCV treatment naïve patients (n = 12) and sustained responders (n = 5) with 
miRNeasy kit (Qiagen). B. Monocytes of healthy controls and chronic HCV treatment naïve 
patients were stimulated with 100 ng/ml LPS for 6-8 h. TaqMan miRNA assay (Applied 
Biosystems) was used for detection of miR-155. RNU48 was used as a normalization control. 
The non-parametric Mann–Whitney test was employed for statistical analysis 
While miR-155 increases TNFα production, miR-125b and miR-146a have negative 
regulatory effects on TNFα [15,19]. We found reduced miR-125b and no change in miR-146a 
in monocytes of patients with cHCV compared to HCV-responders and normal controls 
(Figure 2A and B). 
Figure 2 Decreased miR-125b expression in peripheral monocytes of chronic HCV 
treatment naïve patients. A-B. Total RNA was isolated from monocytes of healthy 
volunteers (n = 6), chronic HCV treatment naïve patients (n = 12) and sustained responders 
(n = 5) with miRNeasy kit (Qiagen). MiR-125b and miR-146a levels were detected by 
TaqMan miRNA assay (Applied Biosystems), and RNU48 was used as a normalization 
control. The non-parametric Mann–Whitney test was employed for statistical analysis 
Increased TNFα and TLR8 expression in monocytes of HCV infected patients 
In a previous study, we reported increased TNFα production by monocytes from patients with 
cHCV [6]. Here, we also found increased TNFα mRNA expression in monocytes of cHCV 
patients (Figure 3A). Because increased TNFα production could be induced by ligands for 
TLR4 (LPS, NS5), TLR2 (HCV core and NS3 proteins) or TLR8 (single-stranded RNA), we 
evaluated the expression of these TLRs in monocytes. We found no difference in baseline 
TLR4 expression between monocytes from cHCV infected patients and normal controls, and 
TLR4 mRNA was decreased in both groups after LPS stimulation (Figure 3B). In contrast, 
TLR8 mRNA levels were significantly higher in monocytes from cHCV-infected patients and 
showed upregulation after an in vitro LPS challenge (Figure 3C). There were no significant 
changes in TLR1, TLR2 and TLR6 levels in monocytes between cHCV and normal controls 
with or without LPS stimulation (data not shown). 
Figure 3 Increased TNFα and TLR8 expression in peripheral monocytes of chronic 
HCV treatment naïve patients. A-C. Total RNA was isolated from monocytes of healthy 
volunteers treated or not (n = 6-8), and from chronic HCV treatment naïve patients stimulated 
or not (n = 9-10) with 100 ng/ml LPS for 6-8 h. Real time PCR was carried out using gene-
specific primers for TNFα (A), TLR4 (B) and TLR8 (C) expression. 18 S was used as a 
normalization control and the non-parametric Mann–Whitney test was employed for 
statistical analysis 
HCV core, NS3 and NS5 proteins and TLR4 and TLR8 ligands increase miR-
155 levels in human monocytes 
MicroRNA-155 has recently been identified as a positive regulator of TNFα production [19]. 
Because increased expression of TNFα in the liver and in blood monocytes was previously 
found in cHCV and TLR ligands, and HCV proteins were shown to induce TNFα in 
monocytes, we tested the effect of these TLR ligands on miR-155 induction [6,10,20]. Here 
we found increased miR-155 levels in normal monocytes after stimulation with the TLR4 
ligand, LPS (Figure 4A). HCV is a single stranded RNA virus that can be recognized by 
TLR7 and/or TLR8 of which TLR8 is expressed in monocytes [10,16]. We found that the 
TLR8 ligand, CLO75, increased miR-155 levels in monocytes compared to unstimulated 
cells (Figure 4A). Multiple mechanisms have been suggested for increased TNFα production 
in monocytes of patients with chronic HCV infection including circulating HCV core protein 
[6,9,21]. Our results show that stimulation with recombinant HCV core or NS3 or NS5 
proteins significantly increased monocyte miR-155 expression in normal human monocytes 
(Figure 4A). In contrast, E2 (viral envelop protein, E2) failed to induce miR-155 expression 
in monocytes (Figure 4A). Parallel to miR-155 induction, LPS, CLO75, HCV core, NS3 and 
NS5 all induced significant increases in TNFα mRNA (Figure 4B) and protein levels (Figure 
4C). Furthermore, we found that E2 protein also resulted in a moderate but significant 
increase in TNF TNFα, both at mRNA and protein levels (Figure 4B & C). 
Figure 4 Viral NS3, NS5 and core proteins and TLR4 and TLR8 ligands induce miR-
155 and TNFα in monocytes of healthy controls. A-B. Monocytes of healthy controls 
(n = 5) were stimulated or not with 100 ng/ml LPS (TLR4 ligand), 5ug/ml CLO75 (TLR8 
ligand), 5ug/ml viral core protein, NS3 and NS5 proteins (non-structural viral proteins), and 
E2 (viral envelop protein) for 6-8 h. The experiment was performed in duplicates. A. Total 
RNA was isolated and subjected to TaqMan miRNA assay for miR-155. B&C. TNFα mRNA 
expression was examined by real time PCR (B) and protein levels were determined by ELISA 
in cell-free supernatants (C). Two-tailed t-test was used for statistical analysis 
Increased miR-155 in the serum of patients with chronic HCV infection 
Increasing evidence suggests that circulating micro-RNAs may serve as biomarkers in 
disease conditions [22]. Here we tested serum levels of miR-155 and found a statistically 
significant increase in serum miR-155 levels in patients with chronic HCV infection (cHCV) 
compared to normal controls (Figure 5A). Serum levels of miR-125b and miR-146a were also 
increased in cHCV patients compared to normal controls (Figure 5B and C). 
Figure 5 Increased serum miR-155, miR-125b and miR-146a levels in chronic HCV-
infected patients. A-C. 100ul of serum was used for total RNA isolation from both healthy 
controls (n = 12-18) and chronic HCV patients (n = 30-36) with miRNeasy kit (Qiagen). 
TaqMan miRNA assays (Applied Biosystems) were used to detect miRNA levels and 
C.elegans (Cel)-miR-39 was used to normalize the ct values. The non-parametric Mann–
Whitney test was used for statistical analysis 
Increased levels of miR-122 in the serum of patients with chronic HCV 
infection 
Elevated serum or plasma miR-122 has been found in correlation with liver injury in recent 
studies [23-26]. We found that patients with chronic HCV infection had significantly 
increased serum miR-122 levels compared to controls (Figure 6A). In the same patients, 
serum levels of ALT and AST were also elevated (Figure 6B) and this finding was consistent 
with the presence of chronic HCV infection. There was a strong correlation between serum 
ALT/AST and serum miR-122 increases (Figure 6C&D). Importantly, a correlation between 
serum miR-155 and miR-122 levels was found in cHCV patients (Figure 6E). These data 
suggest that circulating micro-RNAs may reflect disease activity in chronic HCV infection. 
Figure 6 Increased circulating miR-122 levels correlate with serum ALT, AST and miR-
155 levels in chronic HCV-infected patients. A. 100ul of serum was used for total RNA 
isolation from both healthy controls (n = 12-13) and chronic HCV patients (n = 33) with 
miRNeasy kit (Qiagen). Serum miR-122 levels were detected with TaqMan miRNA assay as 
described in the methods. The non-parametric Mann–Whitney test was used for statistical 
analysis. B. Serum ALT or AST levels of healthy and chronic HCV-infected individuals. C-
E. Correlation between serum miR-122 and ALT (C) and AST (D) and serum miR-155 (E) 
was determined with the Spearman method 
Discussion 
Chronic hepatitis from HCV infection is characterized by ongoing immune activation and a 
low-grade inflammation in the liver and in the periphery that accompanies the liver injury 
[13,27]. While numerous studies reported the presence of inflammatory cascade activation, 
the mechanisms that trigger and sustain the increased TNFα and inflammatory cell activation 
remain elusive [2,27,28]. Micro-RNAs have emerged as key regulators of inflammation of 
which miR-155 has a unique positive regulatory effect on TNFα production [19,29]. In this 
report, we tested the hypothesis that micro-RNAs are dysregulated in chronic HCV infection. 
We found that treatment-naïve patients with chronic HCV infection have increased 
expression of miR-155 in their circulating monocytes that are the major sources of TNFα 
production. Importantly, miR-155 levels were not increased in monocytes from patients who 
have successfully cleared HCV infection after therapy, suggesting a possible correlation 
between increased miR-155 and HCV viral presence and/or replication. We also found that 
cHCV monocytes have increased mRNA expression of TLR8, a receptor for single-stranded 
RNA and showed that in normal monocytes not only TLR4 and TLR8 ligands but HCV core, 
NS3 and NS5 proteins induced miR-155 upregulation. MiR-155 was elevated both in the 
monocytes and in the serum compartment in chronic HCV infection, and this occurred in the 
presence of increased serum miR-122. Together, our results suggest that miR-155 
upregulation in HCV infection in monocytes may contribute to the increased pro-
inflammatory state and raises the possibility that circulating miRNAs could serve as disease 
markers. 
Increased miR-155 levels in circulating monocytes of HCV patients may have several 
implications for disease development and progression. First, miR-155 over-expression in 
monocytes and macrophages has been shown to sensitize to stimulation with LPS [17,19]. 
Indeed, we not only found increased baseline miRNA-155 expression but also a significant 
upregulation of miR-155 after in vitro LPS challenge in cHCV infection. Previous studies 
from our and other laboratories demonstrated that monocytes from chronic HCV infected 
patients have increased baseline TNFα production as well as hyper-responsiveness to ex vivo 
stimulation with LPS, suggesting that increased miR-155 levels may contribute to the over-
activation of the pro-inflammatory phenotype of monocytes. This notion is supported by 
reports where knock-down of miR-155 or miR-155-deficient mice showed attenuated TNFα 
production to LPS stimulation [17,30,31]. Intriguingly, various studies have demonstrated 
TNFα as a positive regulator of miR-155, indicating a positive feed back regulation [32]. 
Based on our results, it is tempting to speculate that increased miR-155 sensitizes monocytes 
to a TLR-induced trigger for TNFα production in active HCV infection. In parallel to our 
work, a recent study showed that expression of BIC gene, a precursor of mature miR-155, 
was increased in PBMCs of HCV-infected patients [33]. They further demonstrated that the 
highest expression of BIC was found in patients harboring HCV RNA in serum and PBMCs 
whereas lowest BIC expression was observed in patients that eliminated HCV RNA from 
both serum and PBMCs after anti-viral treatment, suggesting a correlation between HCV 
RNA and precursor levels of miR-155 [33]. Moreover, a correlation between miR-155 
expression and HCV replication has been demonstrated in PBMCs of chronic hepatitis C 
patients [34]. Our findings further indicate an increase of mature miR-155 in monocytes and 
serum of cHCV patients. Although we found no significant changes in miR-146a levels in 
monocytes of cHCV patients, some of patients who had higher miR-146a levels also showed 
higher levels of miR-155 and miR-125b. A large-scale clinical study might answer if the 
variability between miRNAs correlates with HCV viral load or progression of HCV infection. 
Our observations also suggest that HCV-related TLR ligands provide the possible 
mechanisms for in vivo induction of miR-155 and monocyte activation in cHCV patients 
[13]. For example, high levels of HCV core protein as well as LPS are present in patients 
with cHCV [6,35]. Our data show that both HCV core protein and LPS induce miR-155 in 
normal monocytes. It has been shown that HCV core protein can activate monocytes and DCs 
via TLR2 and the complement C1q receptor [9,18]. In addition, HCV NS3 protein that 
activates TLR2, also increased monocyte miR-155 in our hands. A recent study reported the 
induction of TNFα in response to NS5 (non-structural viral protein) treatment in human 
Kupffer cells [11]. In agreement with this study, we found induction of miR-155 and TNF α 
in monocytes treated with NS5. NS5 has been shown to activate the TLR4 pathway [36]. 
Previously, it has been shown that viral E2 protein interacts with CD81 and increases the 
expression of activation-induced cytidine deaminase and TNFα production in B cells [12]. 
We also found a moderate increase of TNFα in monocytes treated with E2 protein without 
any change in miR-155 levels. Our data suggest that viral E2 protein can induce TNFα 
independent of miR-155, however, further studies are needed to confirm these findings. 
Finally, we found that TLR8 ligand activation can increase miR-155 and TNFα production 
and it is feasible that HCV, as a single-stranded RNA, induces miR-155 in monocytes via 
TLR8. Together our data demonstrate that multiple, HCV-associated TLR ligands are likely 
to be involved in miR-155 induction in cHCV infection. 
We not only found increased miR-155 and miR-122 levels in the serum of cHCV patients but 
levels of miR-125b and miR-146a were also increased. Increased circulating miR-125b levels 
have been found in various cancers and recently, it has been reported that increased 
circulating miR-125b levels were associated with chemotherapeutic resistance in breast 
cancer [37]. The significance of increased miR-125b in HCV patients awaits further 
investigation. Circulating miR-146a levels were shown to be increased in patients with type 2 
diabetes [38]. Interestingly, HCV is known to induce type 2 diabetes [39], and it is tempting 
to speculate that increased miR-146a in the circulation might predispose the individuals to 
HCV infection or vice versa. 
Although, there are many studies depicting the increased circulating miRNAs in various 
etiologies, the source of circulating miRNAs is not as clear. The liver is a complex organ 
where various cell types reside and interact in close vicinity. In our study, there could be 
multiple factors that contribute to induction of miRNAs (miR-122, miR-155, miR-146a and 
miR-125b) in the circulation during HCV infection. The possibility that these miRNAs are 
either released from immune cells in a non-specific manner or are released from different cell 
types in a cell-specific manner in response to HCV infection cannot be ruled out. It is most 
likely that miR-122 is released from damaged hepatocytes. In agreement with this, we found 
increased levels of miR-122 in the supernatant of JFH-1 or J6/JFH-1 infected HuH7.5 cells 
(data not shown). Recent studies suggest that miR-155 is not only limited to immune cells 
(dendritic cells, Kuffper cells, monocytes, NK cells, T cells), but also prevalent in non-
immune cells (hepatocytes, endothelial cells). We have recently reported that chronic alcohol 
feeding increases miR-155 not only in Kuffper cells but also in hepatocytes [40], and it has 
been shown that alcoholic hepatitis patients have a higher prevalence of HCV infection [41]. 
Our preliminary results suggest a moderate increase of miR-155 in the supernatant of JFH-1 
or J6/JFH-1 infected cells compared to uninfected HuH7.5 cells (data not shown). On the 
basis of these findings, it is most likely that both immune cells and hepatocytes contribute to 
increase of miR-155 in the circulation in HCV infection. Further studies are warranted to 
investigate the cellular source of circulating miRNAs. 
Growing evidences suggest that circulating miRNAs may be affected by age and body weight 
and it was reported that levels of circulating miRNA-155 inversely correlated with age in 
patients with coronary artery disease [42]. Whether these factors affect the outcome of 
circulating miRNAs in HCV patients needs to be investigated. Finally, we found increased 
miR-122 levels in the serum of chronic HCV infected patients, which strongly correlated with 
liver damage markers such as ALT and AST. The correlation of serum miR-122 was more 
robust with ALT than AST. Our results support the previous findings where a strong 
correlation between serum miR-122 and ALT/AST increases has been reported [43,44]. 
Interestingly, our data indicates a positive correlation between serum miR-155, an 
inflammation-related miRNA, and miR-122, a hepatocyte-specific micro-RNA. We speculate 
that this could be related to inflammation-induced hepatocyte damage that occurs in chronic 
HCV infection. In our patient cohort, there was no significant correlation between ALT 
values and serum miR-155 expression. Further investigation of serum miRNAs and their role 
as diagnostic biomarkers or biological mediators deserves attention. 
Conclusions 
Our study demonstrates that monocytes have increased miR-155 expression and increased 
TNFα production in patients with chronic HCV infection. The observation that miR-155 is 
induced in monocytes by TLR4 and TLR8 stimulation as well as by HCV core, NS3 and NS5 
proteins suggests potential mechanisms for in vivo miR-155 induction in chronic HCV 
infection. Our finding of increased serum miR-155 and miR-122 and their correlation implies 
that microRNAs deserve investigations as potential biomarkers in disease activity. 
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